Pfizer On Lung Cancer: "We Need To Have Single-Agent Avelumab"
President-Pfizer Oncology Liz Barrett said the company remains committed to demonstrating the value of Bavencio in first-line lung cancer despite a recent setback that will push data out to 2019.
You may also be interested in...
FDA's approval of Merck's Keytruda/chemo combo based on Phase II data secures the company's position in the prized first-line lung cancer indication, but Phase III readouts from other combination trials are right around the corner.
Pfizer got Bavencio to market by focusing on an unmet need, but the PD-L1 inhibitor is still a few years behind, competing with other checkpoint inhibitors over more valuable indications.
Major changes to Phase III Lung 100 study of PD-L1 inhibitor avelumab mean a big delay for development in first-line lung cancer, but, separately, Pfizer advances in allogeneic CAR-T therapy with partners Servier and Cellectis.